Clinical efficacy of entecavir and lamivudine on HBeAg positive chronic hepatitis B patients
10.13699/j.cnki.1001-6821.2015.14.001
- VernacularTitle:恩替卡韦与拉米夫定治疗 e抗原阳性慢性乙型病毒性肝炎的临床研究
- Author:
Xiao-Jie XU
1
;
Zi-Li REN
;
Lei HUANG
Author Information
1. 杭州市中医院感染科
- Keywords:
entecavir;
lamivudine;
HBeAg positive;
chronic hepatitis B;
HBeAg seroeonversion
- From:
The Chinese Journal of Clinical Pharmacology
2015;(14):1363-1365
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and safety of entecavir and lamivudine on patients with hepatitis B e antigen( HBeAg) positive chro-nic hepatitis B.Methods A total of 80 patients with HBeAg positive chronic hepatitis B were randomly divided into trial group and control group , with 40 cases each.The patients in trial group were given entecvir 500 mg? d-1;and those in the control group were given lamivudine 100 mg? d-1 .The treatment course of both groups was 48 weeks.The data of ALT normalization rate, rate of undetectable HBV DNA and HBeAg seroeonversion rate in two groups at the 8th, 12th, 24th, 36thand 48thweek after treatment were compared as well as the differences of adverse reac-tions during treatment.Results The ALT normalization rate in trial group was 47.50%, 65.00% at the 8th, 12thweek, significantly higher than those of the control group ( 25.00%, 42.50%) ( P <0.05 ) .The rate of undetectable HBV DNA in trial group was significantly higher than control group at each time point ( P<0.05) .The HBeAg seroconversion rate was 32.50%, 35.00% at the 36th and 48th week in trial group, significantly higher than that of the control group (12.50%,15.00%) ( P<0.05) .The incidence of adverse reactions between the two groups had no statistical difference ( P >0.05 ) .Conclusion The entecavir treatment for HBeAg positive chronic hepatitis B patients is with good curative effect, lower incidence of adverse reactions.
